Published in Atherosclerosis on December 26, 2007
The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials (2011) 2.59
Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease. JAMA (2010) 1.71
The Mediterranean diet, its components, and cardiovascular disease. Am J Med (2014) 1.61
Detection of omega-3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters. J Lipid Res (2009) 1.42
The role of triglycerides in atherosclerosis. Curr Cardiol Rep (2011) 1.38
omega-3 polyunsaturated fatty acid supplementation for the treatment of heart failure: mechanisms and clinical potential. Cardiovasc Res (2009) 1.32
Fatty acid regulation of hepatic lipid metabolism. Curr Opin Clin Nutr Metab Care (2011) 1.22
Inverse association of erythrocyte n-3 fatty acid levels with inflammatory biomarkers in patients with stable coronary artery disease: The Heart and Soul Study. Atherosclerosis (2008) 1.22
Fish oil -- how does it reduce plasma triglycerides? Biochim Biophys Acta (2011) 1.20
Omega-3 fatty acids and dementia. Prostaglandins Leukot Essent Fatty Acids (2009) 1.15
Blood eicosapentaenoic and docosahexaenoic acids predict all-cause mortality in patients with stable coronary heart disease: the Heart and Soul study. Circ Cardiovasc Qual Outcomes (2010) 1.13
Basal omega-3 fatty acid status affects fatty acid and oxylipin responses to high-dose n3-HUFA in healthy volunteers. J Lipid Res (2012) 1.12
Fish consumption, marine omega-3 fatty acids, and incidence of heart failure: a population-based prospective study of middle-aged and elderly men. Eur Heart J (2009) 1.08
Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high-fat-fed mice. Nutr Metab (Lond) (2011) 1.03
Polyunsaturated fatty acids and cardiovascular disease: implications for nutrigenetics. J Nutrigenet Nutrigenomics (2009) 1.01
Dietary ω-3 fatty acid and fish intake and incident age-related macular degeneration in women. Arch Ophthalmol (2011) 1.00
Atherosclerosis, dyslipidemia, and inflammation: the significant role of polyunsaturated Fatty acids. ISRN Inflamm (2013) 0.97
Association of serum n-6 and n-3 polyunsaturated fatty acids with lipids in 3 populations of middle-aged men. Am J Clin Nutr (2009) 0.95
Alpha-linolenic acid: is it essential to cardiovascular health? Curr Atheroscler Rep (2010) 0.94
Fatty fish, marine omega-3 fatty acids and incidence of heart failure. Eur J Clin Nutr (2010) 0.93
Low- and high-dose plant and marine (n-3) fatty acids do not affect plasma inflammatory markers in adults with metabolic syndrome. J Nutr (2011) 0.93
Fish intake and risks of total and cause-specific mortality in 2 population-based cohort studies of 134,296 men and women. Am J Epidemiol (2013) 0.91
Role of superoxide radical anion in the mechanism of apoB100 degradation induced by DHA in hepatic cells. FASEB J (2011) 0.87
Dairy products and plasma cholesterol levels. Food Nutr Res (2010) 0.87
Omega-3 fatty acid therapy reduces triglycerides and interleukin-6 in hypertriglyeridemic HIV patients. HIV Med (2013) 0.87
A review on the traditional Chinese medicinal herbs and formulae with hypolipidemic effect. Biomed Res Int (2014) 0.87
Eicosapentaenoic acid-enriched phospholipid ameliorates insulin resistance and lipid metabolism in diet-induced-obese mice. Lipids Health Dis (2013) 0.86
Diabetes Dyslipidemia. Diabetes Ther (2016) 0.85
Effect of Echium oil compared with marine oils on lipid profile and inhibition of hepatic steatosis in LDLr knockout mice. Lipids Health Dis (2013) 0.84
Anti-Inflammatory Diet for Atherosclerosis and Coronary Artery Disease: Antioxidant Foods. Clin Med Insights Cardiol (2015) 0.84
Complementary and alternative medicine usage among cardiac patients: a descriptive study. BMC Complement Altern Med (2015) 0.84
Functional foods and nutraceuticals in the primary prevention of cardiovascular diseases. J Nutr Metab (2012) 0.84
Long-term treatment with the pan-PPAR agonist tetradecylthioacetic acid or fish oil is associated with increased cardiac content of n-3 fatty acids in rat. Lipids Health Dis (2012) 0.84
The impact of omega-3 polyunsaturated fatty acid supplementation on the incidence of cardiovascular events and complications in peripheral arterial disease: a systematic review and meta-analysis. BMC Cardiovasc Disord (2014) 0.83
Beneficial effects of omega-3 fatty acids in the proteome of high-density lipoprotein proteome. Lipids Health Dis (2012) 0.83
The role of long-chained marine N-3 polyunsaturated Fatty acids in cardiovascular disease. Cardiol Res Pract (2012) 0.83
Looking Beyond the Terrestrial: The Potential of Seaweed Derived Bioactives to Treat Non-Communicable Diseases. Mar Drugs (2016) 0.82
Association of an ACSL1 gene variant with polyunsaturated fatty acids in bovine skeletal muscle. BMC Genet (2011) 0.81
Significant inverse association of marine n-3 fatty acids with plasma fibrinogen levels in Japanese in Japan but not in whites or Japanese Americans. Eur J Clin Nutr (2011) 0.81
Effects of ω-3 polyunsaturated fatty acids on plasma proteome in Rett syndrome. Mediators Inflamm (2013) 0.80
Aspirin enhances protective effect of fish oil against thrombosis and injury-induced vascular remodelling. Br J Pharmacol (2015) 0.80
Association between the intake of α-linolenic acid and the risk of CHD. Br J Nutr (2014) 0.80
Dietary sources, current intakes, and nutritional role of omega-3 docosapentaenoic acid. Lipid Technol (2015) 0.79
The association between marine n-3 polyunsaturated fatty acid levels and survival after renal transplantation. Clin J Am Soc Nephrol (2015) 0.79
Supplementation of krill oil with high phospholipid content increases sum of EPA and DHA in erythrocytes compared with low phospholipid krill oil. Lipids Health Dis (2015) 0.79
Two fatty acid elongases possessing C18-Δ6/C18-Δ9/C20-Δ5 or C16-Δ9 elongase activity in Thraustochytrium sp. ATCC 26185. Mar Biotechnol (NY) (2013) 0.79
Omega-3 Fatty Acid Supplementation for 12 Weeks Increases Resting and Exercise Metabolic Rate in Healthy Community-Dwelling Older Females. PLoS One (2015) 0.79
Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report. Cardiovasc Diabetol (2009) 0.79
Marine fish oils are not equivalent with respect to B-cell membrane organization and activation. J Nutr Biochem (2014) 0.78
Effects of docosahexaenoic Acid supplementation on blood pressure, heart rate, and serum lipids in Scottish men with hypertension and hypercholesterolemia. Int J Hypertens (2011) 0.78
Poly is more effective than monounsaturated fat for dietary management in the metabolic syndrome: The muffin study. J Clin Lipidol (2016) 0.77
Importance of fatty acid compositions in patients with peripheral arterial disease. PLoS One (2014) 0.77
Omega-3 Polyunsaturated Fatty Acids: Structural and Functional Effects on the Vascular Wall. Biomed Res Int (2015) 0.77
Bioequivalence of two omega-3 fatty acid ethyl ester formulations: a case of clinical pharmacology of dietary supplements. Br J Clin Pharmacol (2012) 0.77
Diets Enriched in Fish-Oil or Seal-Oil have Distinct Effects on Lipid Levels and Peroxidation in BioF1B Hamsters. Nutr Metab Insights (2011) 0.77
Association between fish and shellfish, and omega-3 PUFAs intake and CVD risk factors in middle-aged female patients with type 2 diabetes. Nutr Res Pract (2015) 0.77
Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial. Lipids Health Dis (2015) 0.77
Associations between Serum Omega-3 Fatty Acid Levels and Cognitive Functions among Community-Dwelling Octogenarians in Okinawa, Japan: The KOCOA Study. J Alzheimers Dis (2016) 0.76
A calorie-restriction diet supplemented with fish oil and high-protein powder is associated with reduced severity of metabolic syndrome in obese women. Eur J Clin Nutr (2014) 0.76
Modified Mediterranean Diet for Enrichment of Short Chain Fatty Acids: Potential Adjunctive Therapeutic to Target Immune and Metabolic Dysfunction in Schizophrenia? Front Neurosci (2017) 0.75
Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia. Vasc Health Risk Manag (2016) 0.75
Reconstruction of Danio rerio metabolic model accounting for subcellular compartmentalisation. PLoS One (2012) 0.75
Supplementing long-chain n-3 polyunsaturated fatty acids in canned wild Pacific pink salmon with Alaska salmon oil. Food Sci Nutr (2013) 0.75
Flaxseed oil increases aortic reactivity to phenylephrine through reactive oxygen species and the cyclooxygenase-2 pathway in rats. Lipids Health Dis (2014) 0.75
Omega-3 supplements and cardiovascular diseases. Tanaffos (2014) 0.75
A fish a day, keeps the cardiologist away! - A review of the effect of omega-3 fatty acids in the cardiovascular system. Indian J Endocrinol Metab (2013) 0.75
Plasma levels of marine n-3 fatty acids and cardiovascular risk markers in renal transplant recipients. Eur J Clin Nutr (2016) 0.75
Epigenetic changes in blood leukocytes following an omega-3 fatty acid supplementation. Clin Epigenetics (2017) 0.75
Effect of Omega-3 Supplementation on Visfatin, Adiponectin, and Anthropometric Indices in Women with Polycystic Ovarian Syndrome. J Reprod Infertil (2016) 0.75
Role of n-3 Polyunsaturated Fatty Acids in Ameliorating the Obesity-Induced Metabolic Syndrome in Animal Models and Humans. Int J Mol Sci (2016) 0.75
The Effectiveness of a Bioactive Food Compound in the Lipid Control of Individuals with HIV/AIDS. Nutrients (2016) 0.75
Dietary supplementation with fish gelatine modifies nutrient intake and leads to sex-dependent responses in TAG and C-reactive protein levels of insulin-resistant subjects. J Nutr Sci (2012) 0.75
Supplementation with omega-3 fish oil has no effect on bone mineral density in adults with knee osteoarthritis: a 2-year randomized controlled trial. Osteoporos Int (2015) 0.75
Effects of improved fat content of frankfurters and pâtés on lipid and lipoprotein profile of volunteers at increased cardiovascular risk: a placebo-controlled study. Eur J Nutr (2013) 0.75
Vegan diets: practical advice for athletes and exercisers. J Int Soc Sports Nutr (2017) 0.75
Significance of long chain polyunsaturated fatty acids in human health. Clin Transl Med (2017) 0.75
Bioavailability of n-3 fatty acids from n-3-enriched foods and fish oil with different oxidative quality in healthy human subjects: a randomised single-meal cross-over study. J Nutr Sci (2016) 0.75
Design and implementation of microarray gene expression markup language (MAGE-ML). Genome Biol (2002) 16.75
Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA (2005) 9.61
Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med (2009) 9.35
A simple spreadsheet-based, MIAME-supportive format for microarray data: MAGE-TAB. BMC Bioinformatics (2006) 7.53
Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest (2009) 7.09
Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA (2007) 6.95
Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA (2002) 6.48
Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA (2003) 6.17
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol (2003) 5.77
Pattern separation in the human hippocampal CA3 and dentate gyrus. Science (2008) 5.56
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA (2006) 4.90
AACE comprehensive diabetes management algorithm 2013. Endocr Pract (2013) 4.88
A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science (2008) 4.50
Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation (2006) 4.25
The first RSBI (ISA-TAB) workshop: "can a simple format work for complex studies?". OMICS (2008) 4.15
Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med (2006) 3.90
The Functional Genomics Experiment model (FuGE): an extensible framework for standards in functional genomics. Nat Biotechnol (2007) 3.55
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med (2004) 3.49
Direct care workers in the National Drug Abuse Treatment Clinical Trials Network: characteristics, opinions, and beliefs. Psychiatr Serv (2007) 3.38
ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA (2009) 3.33
American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract (2013) 2.97
Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthalmol (2010) 2.78
Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology (2003) 2.61
Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol (2005) 2.61
Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med (2002) 2.59
Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med (2003) 2.56
HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem (2011) 2.33
Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation (2005) 2.21
Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol (2009) 2.19
Low-fat diets and weight change. JAMA (2006) 2.19
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol (2005) 2.16
Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther (2004) 2.14
Organizational Readiness for Change and opinions toward treatment innovations. J Subst Abuse Treat (2007) 2.14
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet (2013) 2.11
Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol (2006) 2.07
Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial. Arterioscler Thromb Vasc Biol (2002) 2.07
Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study. Clin Chem (2004) 2.05
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the joslin 50-year medalist study. Diabetes Care (2011) 2.00
High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol (2004) 2.00
The Marijuana Treatment Project: rationale, design and participant characteristics. Addiction (2002) 1.94
Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux. J Lipid Res (2005) 1.83
Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Arch Ophthalmol (2004) 1.80
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol (2006) 1.76
Image-based estimation of ventricular fiber orientations for personalized modeling of cardiac electrophysiology. IEEE Trans Med Imaging (2012) 1.72
Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol (2004) 1.71
Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis (2009) 1.68
Treatment programs in the National Drug Abuse Treatment Clinical Trials Network. Drug Alcohol Depend (2007) 1.64
A chloroplast transgenic approach to hyper-express and purify Human Serum Albumin, a protein highly susceptible to proteolytic degradation. Plant Biotechnol J (2003) 1.64
Familial defective apolipoprotein B-100 and increased low-density lipoprotein cholesterol and coronary artery calcification in the old order amish. Arch Intern Med (2010) 1.64
Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther (2003) 1.63
Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am J Cardiol (2011) 1.60
Rising national prevalence of life-limiting conditions in children in England. Pediatrics (2012) 1.59
Risk of cardiovascular disease in a cohort of HIV-infected adults: a study using carotid intima-media thickness and coronary artery calcium score. Clin Infect Dis (2006) 1.54
Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin (2006) 1.53
Trisodium citrate 46.7% selectively and safely reduces staphylococcal catheter-related bacteraemia. Nephrol Dial Transplant (2008) 1.52
Metabolic and functional relevance of HDL subspecies. Curr Opin Lipidol (2011) 1.52
Controversy surrounding the safety of cerivastatin. Expert Opin Drug Saf (2002) 1.50
High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol (2013) 1.50
Lipoprotein response to diets high in soy or animal protein with and without isoflavones in moderately hypercholesterolemic subjects. Arterioscler Thromb Vasc Biol (2002) 1.50
ABCA1(Alabama): a novel variant associated with HDL deficiency and premature coronary artery disease. Atherosclerosis (2002) 1.49
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr (2013) 1.48
Role of LCAT in HDL remodeling: investigation of LCAT deficiency states. J Lipid Res (2006) 1.47
In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther (2007) 1.46
Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia. Cardiology (2011) 1.46
Patient satisfaction, prescription drug abuse, and potential unintended consequences. JAMA (2012) 1.45
Hypertriglyceridemic waist phenotype predicts increased visceral fat in subjects with type 2 diabetes. Diabetes Care (2009) 1.43
Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol (2005) 1.43
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol (2008) 1.43
Aace/Ace comprehensive diabetes management algorithm 2015. Endocr Pract (2015) 1.43
Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study. Clin Chem (2010) 1.43
The two novel CETP mutations Gln87X and Gln165X in a compound heterozygous state are associated with marked hyperalphalipoproteinemia and absence of significant coronary artery disease. J Mol Med (Berl) (2006) 1.42
Resistance to chronic wasting disease in transgenic mice expressing a naturally occurring allelic variant of deer prion protein. J Virol (2007) 1.41
Relationship of abdominal visceral and subcutaneous adipose tissue with lipoprotein particle number and size in type 2 diabetes. Diabetes (2008) 1.41
FuGE: Functional Genomics Experiment Object Model. OMICS (2006) 1.39
The editor's roundtable: JUPITER follow-up. Am J Cardiol (2011) 1.39
The Oak Ridge Polycystic Kidney mouse: modeling ciliopathies of mice and men. Dev Dyn (2008) 1.36
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol (2010) 1.36
Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol (2008) 1.35
Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care (2003) 1.35
Does glycemic variability impact mood and quality of life? Diabetes Technol Ther (2012) 1.35
Genetic variation at the scavenger receptor class B type I gene locus determines plasma lipoprotein concentrations and particle size and interacts with type 2 diabetes: the framingham study. J Clin Endocrinol Metab (2003) 1.35
Lead toxicity in a 14-year-old female with retained bullet fragments. Pediatrics (2006) 1.34
A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients. J Virol (2005) 1.32
Chromosomal location plays a role in regulation of aflatoxin gene expression in Aspergillus parasiticus. Appl Environ Microbiol (2002) 1.31
Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology (2003) 1.31
Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients. Atherosclerosis (2005) 1.30
Alterations in cholesterol absorption/synthesis markers characterize Framingham offspring study participants with CHD. J Lipid Res (2009) 1.29
Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay. J Immunol Methods (2004) 1.29
ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin. J Lipid Res (2004) 1.28
Hypertriglyceridemia and cardiovascular risk reduction. Clin Ther (2007) 1.28
Protective effects of fish intake and interactive effects of long-chain polyunsaturated fatty acid intakes on hip bone mineral density in older adults: the Framingham Osteoporosis Study. Am J Clin Nutr (2011) 1.26
Annotare--a tool for annotating high-throughput biomedical investigations and resulting data. Bioinformatics (2010) 1.26
Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol (2003) 1.25